Sirolimus may be an effective treatment for patients with persistent cutaneous sarcoidosis. In a small clinical trial, 7 of 10 patients treated with sirolimus via oral solution had improvements in ...

The FDA has granted Fast Track designation to BM-3103, a novel topical mTOR inhibitor for epidermolysis bullosa simplex currently in phase 2.

Work at Trained Therapeutix Discovery Inc. has led to the development of new mammalian target of rapamycin (mTOR; FRAP1) inhibitors and high-density lipoprotein (HDL)-derived nanoparticles potentially ...

Dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway is frequently observed across a wide range of cancers and contributes to uncontrolled cell proliferation, enhanced ...

Health related quality of life (HRQOL) evaluated with the EORTC C30 questionnaire in first line therapy of elderly patients with chronic lymphocytic leukemia (CLL): Results of a phase III trial of the ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...

The reality of a population who is aging at an accelerated rate makes it a priority to understand what happens in the body over time, on a molecular scale. The mTOR protein complex is known to be ...